Análisis y protocolización de la utilización de rasburicasa en pacientes con neoplasias hematológicas
Reads0
Chats0
TLDR
A high variability is observed in the use of rasburicase in adult patients with hematological neoplasias and a protocol for its administration is presented according to which, depending on the patient´s risk of developing TLS (tumoral lysis syndrome), standard prophylaxis is administered to low-risk patients and rasBuricase is administered initially for 1-3 days to patients with high risk of developed TLS.About:
This article is published in Farmacia Hospitalaria.The article was published on 2006-03-01 and is currently open access. It has received 8 citations till now. The article focuses on the topics: Rasburicase.read more
Citations
More filters
Journal ArticleDOI
Rasburicase in Tumor Lysis Syndrome of the Adult: A Systematic Review and Meta-analysis
TL;DR: Rasburicase is effective in reducing serum uric acid levels in adults with TLS but at a significant cost, and evidence currently is lacking in adults to report whether rasBuricase use improves clinical outcomes compared with other alternatives.
Journal ArticleDOI
Rasburicase in the management of tumor lysis: An evidence-based review of its place in therapy
TL;DR: Rasburicase is now a standard of care for patients at high risk of TLS despite continuing debate on the correlation between its profound and rapid lowering of plasma uric acid levels with hard patient outcomes, eg, need for renal replacement therapy and mortality.
Journal ArticleDOI
Tumor lysis syndrome in intensive therapy: diagnostic and therapeutic encare
TL;DR: Diagnostic tools are provided that allow to the ICU physician to recognize the population at high risk for developing the TLS, and outline a proper strategy for treating and preventing this serious complication.
Journal ArticleDOI
Síndrome de lisis tumoral
TL;DR: This is a female patient who presented tumor lysis syndrome, which constitutes an oncologic emergency as in tumor cells either spontaneously or more often with tumor treatment, uric acid release, potassium and phosphorus.
Journal ArticleDOI
Síndrome de lisis tumoral en terapia intensiva: encare diagnóstico y terapéutico
TL;DR: The TLS can be observed before starting the treatment due to spontaneous tumor cell death, and it worsens when chemotherapy is initiated, so that its prevention continues to be the most important therapeutic measure.
References
More filters
Journal ArticleDOI
Acute tumor lysis syndrome: A review of 37 patients with Burkitt's lymphoma
TL;DR: Renal and metabolic complications of tumor lysis during 46 episodes of remission induction chemotherapy were reviewed in 37 patients with American Burkitt's lymphoma, finding that major complications following chemotherapy were associated with very large tumors, high LDH levels and inadequate urinary output.
Journal ArticleDOI
Recombinant Urate Oxidase for the Prophylaxis or Treatment of Hyperuricemia in Patients With Leukemia or Lymphoma
Ching-Hon Pui,Hazem Mahmoud,Joseph Wiley,Gerald M. Woods,Guy Leverger,Bruce M. Camitta,Caroline Hastings,Susan M. Blaney,Mary V. Relling,Gregory H. Reaman +9 more
TL;DR: Rasburicase is safe and highly effective for the prophylaxis or treatment of hyperuricemia in patients with leukemia or lymphoma, and none of the patients required dialysis.
Journal ArticleDOI
Efficacy and Safety of Rasburicase (recombinant urate oxidase) for the Prevention and Treatment of Hyperuricemia During Induction Chemotherapy of Aggressive Non-Hodgkin’s Lymphoma: Results of the GRAAL1 (Groupe d’Etude des Lymphomes de l’Adulte Trial on Rasburicase Activity in Adult Lymphoma) Study
Bertrand Coiffier,Nicolas Mounier,Serge Bologna,Christophe Fermé,Hervé Tilly,Anne Sonet,B. Christian,Olivier Casasnovas,Eric Jourdan,Karim Belhadj,Raoul Herbrecht +10 more
TL;DR: Rasburicase is the treatment of choice to control UA and prevent tumor lysis syndrome in adult patients with aggressive NHL during their first cycle of chemotherapy.
Journal ArticleDOI
Tumor lysis syndrome.
TL;DR: Novel approaches in the management of TLS include the use of urate oxidase, which can provide effective treatment with an acceptable safety profile, and aggressive hydration might lead to volume overload, specifically in older patients.
Journal ArticleDOI
Rasburicase (recombinant urate oxidase) for the management of hyperuricemia in patients with cancer: Report of an international compassionate use study
André Bosly,Anne Sonet,C. Ross Pinkerton,Geoffrey McCowage,Dominique Bron,Miguel A. Sanz,Hendrik Van den Berg +6 more
TL;DR: Rasburicase, a recombinant urate oxidase that converts uric acid into the soluble compound allantoin, has been shown to control hyperuricemia faster and more reliably than allopurinol.